首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1789370

凝血因子缺乏症市場：依疾病類型、治療類型、劑型、給藥途徑、年齡層、最終使用者和地區分類

Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography

出版日期: 2025年07月07日 | 出版商:

Coherent Market Insights | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

凝血因子缺乏症市場規模預計在 2025 年為 50.1 億美元，預計到 2032 年將達到 89 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 8.2%。

分析範圍		分析詳細資訊
基準年	2024	市場規模（2025年）	50.1億美元
效能數據	2020-2024	預測期	2025-2032
預測期間的複合年成長率（2025-2032年）	8.20%	預計金額（2032年）	89億美元

全球凝血因子缺乏症市場是血液學治療領域的一個重要領域，該領域用於治療罕見但危及生命的遺傳性出血性疾病，其特徵是正常止血所必需的特定凝血因子的缺失或功能障礙。凝血因子缺乏症包括A型血友病A（因子VIII缺乏）、B型血友病（因子IX缺乏）以及罕見的因子I、II、V、VII、X、XI和XIII缺乏症，全球約有40萬人受到影響。

這些疾病表現為出血時間延長、自發性出血和手術風險增加，需要終身管理，包括因子替代療法、預防性治療和新型基因療法。受技術進步和對凝血連鎖機制理解加深的推動，市場已從血漿衍生濃縮物顯著發展到重組因子製劑和延長半衰期療法。醫療保健專業人員意識的提高、診斷能力的提升、病患登記制度的改進以及新興市場專科護理可近性的提高，正在促進市場發展。包括非因子療法、皮下製劑和基因編輯技術在內的創新方法持續改變治療格局，在減輕這些慢性疾病帶來的經濟負擔的同時，為患者提供了更大的便利，改善了生活品質。

市場動態

全球凝血因子缺乏症市場正呈現強勁成長勢頭，這得益於已開發市場和新興市場的許多相互關聯的因素。關鍵的市場促進因素包括：由於診斷技術的改進和新生兒篩檢計畫的擴大，遺傳性出血性疾病的盛行率不斷上升，促進了早期發現和治療。生物技術的進步正在徹底改變治療模式，半衰期延長的重組因子的開發減少了注射次數並提高了患者的依從性，而新型非凝血因子療法（例如艾美珠單抗）則為抑製劑患者提供了替代治療方案。醫療保健支出的不斷成長（尤其是在新興國家），加上宣傳宣傳活動和患者權益倡導活性化的加強，正在擴大市場可及性，並刺激對先進療法的需求。政府支持罕見疾病研究和孤兒藥開發的舉措，例如優惠的監管治療和加速核准途徑，進一步刺激了市場成長。然而，凝血因子濃縮物和先進療法的高昂成本是市場的主要限制因素，限制了資源匱乏地區的醫療服務，並給醫療保健系統帶來了沉重的財務負擔。約25-30%的重度A型血友病A患者會產生中和抗體（抑制物），不僅增加了治療策略的複雜性，也增加了治療成本。新興市場醫療服務提供者的認知度較低、產品分銷所需的低溫運輸基礎設施不足以及不同市場之間複雜的監管規定，這些都帶來了額外的挑戰。血漿衍生產品供應鏈中斷和血漿短缺正在造成市場不確定性。儘管如此，具有潛在功能性治療方法和長期成本效益的基因療法的不斷發展，也帶來了巨大的商機。亞太和拉丁美洲市場對個人化醫療方法、用於遠端患者監護遠端醫療整合以及醫療基礎設施投資的不斷增加，都顯示市場擴張潛力巨大。

本報告的主要特點

本報告對全球凝血因子缺乏症市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和複合年成長率。
它還強調了每個領域的潛在商機，並描述了該市場的一系列有吸引力的投資提案。
它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球凝血因子缺乏症市場的主要企業會根據以下參數進行分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作夥伴關係、市場擴張和行銷策略做出明智的決策。
「全球凝血因子缺乏症市場」報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球凝血因子缺乏症市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 5.01 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.20%	2032 Value Projection:	USD 8.90 Bn

The global coagulation factor deficiency market represents a critical segment within the broader hematology therapeutics landscape, addressing rare but life-threatening inherited bleeding disorders characterized by the absence or dysfunction of specific clotting factors essential for normal hemostasis. Coagulation factor deficiencies encompass a spectrum of conditions including hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and rarer deficiencies involving factors I, II, V, VII, X, XI, and XIII, collectively affecting approximately 400,000 individuals worldwide.

These disorders manifest through prolonged bleeding episodes, spontaneous hemorrhages, and increased surgical risks, necessitating lifelong management through factor replacement therapies, prophylactic treatments, and emerging gene therapies. The market has witnessed substantial evolution from plasma-derived concentrates to recombinant factors and extended half-life products, driven by technological advancements and improved understanding of coagulation cascade mechanisms. Rising awareness among healthcare professionals, enhanced diagnostic capabilities, improved patient registries, and expanding access to specialized care in developing regions contribute to market growth. The therapeutic landscape continues to transform with innovative approaches including non-factor therapies, subcutaneous formulations, and gene editing technologies, offering enhanced convenience and improved quality of life for patients while addressing the substantial economic burden associated with these chronic conditions.

Market Dynamics

The global coagulation factor deficiency market demonstrates robust growth dynamics driven by multiple interconnected factors that shape its trajectory across developed and emerging markets. Primary market drivers include the increasing prevalence of inherited bleeding disorders due to improved diagnostic techniques and expanded newborn screening programs, which enhance early detection and treatment initiation. Technological advancements in biotechnology have revolutionized treatment paradigms, with the development of extended half-life recombinant factors reducing injection frequency and improving patient compliance, while novel non-factor therapies like emicizumab provide alternative treatment options for patients with inhibitors. Rising healthcare expenditure, particularly in emerging economies, coupled with growing awareness campaigns and patient advocacy initiatives, expands market accessibility and drives demand for advanced therapeutics. Government initiatives supporting rare disease research and orphan drug development, including regulatory incentives and expedited approval pathways, further stimulate market growth. However, significant market restraints persist, primarily centered around the prohibitive cost of factor concentrates and advanced therapies, which limit accessibility in resource-constrained settings and create substantial financial burden on healthcare systems. The development of neutralizing antibodies (inhibitors) in approximately 25-30% of severe hemophilia A patients complicates treatment strategies and increases therapeutic costs. Limited awareness among healthcare providers in developing regions, inadequate cold chain infrastructure for product distribution, and regulatory complexities across different markets pose additional challenges. Supply chain disruptions and plasma shortages for plasma-derived products create market volatility. Nevertheless, substantial opportunities emerge from expanding gene therapy developments, which promise potential functional cures and long-term cost-effectiveness. Growing focus on personalized medicine approaches, telemedicine integration for remote patient monitoring, and increasing healthcare infrastructure investments in Asia Pacific and Latin American markets present significant growth potential for market expansion.

Key Features of the Study

This report provides an in-depth analysis of the global coagulation factor deficiency market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global coagulation factor deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Baxter International Inc., CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Novo Nordisk A/S, Pfizer Inc., Bayer AG, Sobi (Swedish Orphan Biovitrum), Biogen Inc., Octapharma AG, Sanofi S.A., Amgen Inc., Genentech, Inc., and UCB S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global coagulation factor deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global coagulation factor deficiency factor.

Market Segmentation

Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
- Hemophilia A (Factor VIII Deficiency)
- Hemophilia B (Factor IX Deficiency)
- Hemophilia C (Factor XI Deficiency)
- Von Willebrand Disease
- Type 1-Mild deficiency of von Willebrand factor (VWF)
- Type 2-Abnormal function of VWF
- Rare Factor Deficiencies
- Factor I (Fibrinogen) Deficiency
- Factor II (Prothrombin) Deficiency
- Factor V Deficiency
- Factor VII Deficiency
- Factor X Deficiency
- Factor XIII Deficiency
Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
- Replacement Therapy
- Plasma-derived Coagulation Factors
- Recombinant Coagulation Factors
- Non-replacement Therapy
- Desmopressin (DDAVP)
- Antifibrinolytics
- Anticoagulants
- Gene Therapy
- Adeno-Associated Virus (AAV) Gene Therapy
- Lentivirus Gene Therapy
- Others (Hormonal Therapy)
Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Lyophilized Powder for Reconstitution
- Liquid Solution for Injection/Infusion
- Oral Formulations
- Nasal Spray
- Other Viral Vector Suspension
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
- Intranasal
- Oral
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Pharmacies
- Hemophilia Treatment Centers
- Homecare Settings
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others (Academic & Research Institutions.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Baxter International Inc.
- CSL Behring
- Grifols S.A.
- Takeda Pharmaceutical Company
- Novo Nordisk A/S
- Pfizer Inc.
- Bayer AG
- Sobi (Swedish Orphan Biovitrum)
- Biogen Inc.
- Octapharma AG
- Sanofi S.A.
- Amgen Inc.
- Genentech, Inc.
- UCB S.A.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Coagulation Factor Deficiency Market, By Disorder Type
- Global Coagulation Factor Deficiency Market, By Treatment Type
- Global Coagulation Factor Deficiency Market, By Dosage Form
- Global Coagulation Factor Deficiency Market, By Route of Administration
- Global Coagulation Factor Deficiency Market, By Age Group
- Global Coagulation Factor Deficiency Market, By End User
- Global Coagulation Factor Deficiency Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hemophilia A (Factor VIII Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hemophilia B (Factor IX Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hemophilia C (Factor XI Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Von Willebrand Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Type 1-Mild deficiency of von Willebrand factor (VWF)
  - Type 2-Abnormal function of VWF
Rare Factor Deficiencies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Factor I (Fibrinogen) Deficiency
  - Factor II (Prothrombin) Deficiency
  - Factor V Deficiency
  - Factor VII Deficiency
  - Factor X Deficiency
  - Factor XIII Deficiency

5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Plasma-derived Coagulation Factors
  - Recombinant Coagulation Factors
Non-replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Desmopressin (DDAVP)
    - Antifibrinolytics
    - Anticoagulants
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Adeno-Associated Virus (AAV) Gene Therapy
  - Lentivirus Gene Therapy
Others (Hormonal Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lyophilized Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liquid Solution for Injection/Infusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oral Formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Viral Vector Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hemophilia Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic & Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Grifols S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sobi (Swedish Orphan Biovitrum)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
UCB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

12. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

13. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

凝血因子缺乏症市場 - 全球及區域分析：按缺乏症類型、按產品類型、按最終用戶、按區域 - 分析與預測（2025-2035 年）

FAQ

凝血因子缺乏症市場：依疾病類型、治療類型、劑型、給藥途徑、年齡層、最終使用者和地區分類

Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography

市場動態

本報告的主要特點

目錄

第1章分析目標與前提條件

第2章市場展望

第3章：市場動態、法規與趨勢分析

4. 全球凝血因子缺乏症市場（依疾病類型）（2020-2032）

5. 全球凝血因子缺乏症市場依治療類型（2020-2032）

6. 全球凝血因子缺乏症市場（依劑型分類）（2020-2032）

7. 全球凝血因子缺乏症市場依給藥途徑分類（2020-2032 年）

8. 全球凝血因子缺乏症市場（依年齡層分類）（2020-2032 年）

9. 全球凝血因子缺乏症市場（依最終使用者分類）（2020-2032 年）

10. 全球凝血因子缺乏症市場（按地區）（2020-2032）

第11章競爭格局

第12章分析師建議

第13章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)

5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)

6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)

7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)

8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)

9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)

10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

凝血因子缺乏症市場：依疾病類型、治療類型、劑型、給藥途徑、年齡層、最終使用者和地區分類

Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography

市場動態

本報告的主要特點

目錄

第1章 分析目標與前提條件

第2章 市場展望

第3章：市場動態、法規與趨勢分析

4. 全球凝血因子缺乏症市場（依疾病類型）（2020-2032）

5. 全球凝血因子缺乏症市場依治療類型（2020-2032）

6. 全球凝血因子缺乏症市場（依劑型分類）（2020-2032）

7. 全球凝血因子缺乏症市場依給藥途徑分類（2020-2032 年）

8. 全球凝血因子缺乏症市場（依年齡層分類）（2020-2032 年）

9. 全球凝血因子缺乏症市場（依最終使用者分類）（2020-2032 年）

10. 全球凝血因子缺乏症市場（按地區）（2020-2032）

第11章競爭格局

第12章 分析師建議

第13章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)

5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)

6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)

7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)

8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)

9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)

10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

第1章分析目標與前提條件

第2章市場展望

第12章分析師建議